Orion Corporation: Managers’ transactions – Ha

ORION CORPORATION MANAGERS’ TRANSACTIONS 15 AUGUST 2024 at 15.30 EEST         

Orion Corporation: Managers’ transactions – Hao Pan

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Hao Pan Position: Other senior manager Issuer: Orion Oyj LEI: 74370029VAHCXDR7B745 Notification type: INITIAL NOTIFICATION Reference number: 74512/4/4

____________________________________________ Transaction date: 2024-08-15 Venue: XLOM Instrument type: SHARE ISIN: FI0009014377 Nature of transaction: DISPOSAL

Transaction details (1): Volume: 1488 Unit price: 46.15 EUR

Aggregated transactions (1): Volume: 1488 Volume weighted average price: 46.15 EUR

Orion Corporation

Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland http://www.orion.fi/en http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.